FEB 02, 2021 7:30 AM PST

Pumping the Brakes on Stomach Cancer Progression

WRITTEN BY: Tara Fernandez

By the time stomach cancer is diagnosed, it’s often bad news for patients. The disease often presents with relatively mild symptoms (heartburn, nausea, and poor appetite) until the advanced stages, at which point there are very limited treatment options available.

Stomach cancer is the fifth most common cancer worldwide with over a million new diagnoses in 2018 alone.

Now, scientists have discovered a nexus between a molecular regulator of inflammation and stomach cancer progression, breaking new ground in how the disease can be managed clinically. The study was published in the journal Gastroenterology.

The research team, led by Lorraine O’Reilly found that eliminating the immune cytokine tumor necrosis factor, or TNF, arrests the progression of stomach cancer. TNF is an inflammatory signaling protein that alerts immune cells to the presence of infection or tissue damage, thus triggering inflammation.

“We discovered that invasive stomach cancers contain high levels of various factors involved in inflammation, including four soluble proteins called cytokines,” explained O’Reilly.

“By removing each of the four cytokines that were elevated in our model, we could assess how important each one was. This revealed that the cytokine TNF was required for the progression of stomach cancer,” she said.

This observation was significant as it points towards a potential therapeutic approach for slowing stomach cancer development before it begins to spread and invade other organs.

TNF-blocking therapeutics are already in the clinic, albeit for a different application: treating rheumatoid arthritis. Follow-up studies by the team are focused on further testing the safety and efficacy of such drugs for treating stomach cancer. 

 

 

Sources: Gastroenterology, WEHI.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 25, 2020
Immunology
The History of Vaccines
NOV 25, 2020
The History of Vaccines
Everyone worldwide is sitting with anticipation, waiting for the right vaccine candidate for the coronavirus outbreak, h ...
DEC 03, 2020
Immunology
Cytokine Storms Aren't to Blame for COVID Respiratory Failures
DEC 03, 2020
Cytokine Storms Aren't to Blame for COVID Respiratory Failures
Many of the life-threatening symptoms of COVID-19 have been pinned on “cytokine storms” — immune syste ...
DEC 09, 2020
Immunology
Antibodies as Warning Signs of a Silent Cardiovascular Killer
DEC 09, 2020
Antibodies as Warning Signs of a Silent Cardiovascular Killer
In atherosclerosis, cholesterol and other fatty deposits build up around the inner walls of an artery, creating a plaque ...
JAN 12, 2021
Immunology
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
JAN 12, 2021
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
The first organ transplant—performed over 60 years ago—was a success because the donor and recipient were id ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
MAR 22, 2021
Immunology
Gene Mutation Keeps Tumors "Cold"
MAR 22, 2021
Gene Mutation Keeps Tumors "Cold"
Immunologists have identified a mechanism through which an oncogene mutation shields pancreatic tumors from immune cells ...
Loading Comments...